Eye on Innovation
Regulation & Policy
- As AI in Mental Health Evolves, One States Wants to Regulate It While Encouraging Innovation
- Medicare Finalized Coverage for Some Mental Health Apps. Now What?
- Enabling Clinical Trial Innovation Through AI Regulation at FDA
- Six Questions About Medicare’s Proposed Plan to Cover Digital Therapeutics
- CMS Proposes New Payments for Digital Health Under CY2025 PFS Draft Rule
- Surgeon General Calls for Warning Labels on Social Media Platforms
- DEA Close to Unveiling New Telehealth Regulations for Controlled Substance Prescriptions
- Digital Therapeutics Alliance To Launch Accreditation Program to Help Dtx Products Gain Uptake with Payers
- Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn™, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms